Future Science Group
Browse

Infographic – Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Download (10.81 MB)
Version 3 2022-07-12, 13:25
Version 2 2022-07-11, 09:52
Version 1 2022-07-11, 09:44
figure
posted on 2022-07-12, 13:25 authored by Taylor & FrancisTaylor & Francis, Martin Wermke, Enriqueta Felip, Valentina Gambardella, Yasutoshi Kuboki, Daniel Morgensztern, Zohra Oum’ Hamed, Meiruo Liu, Matus Studeny, Taofeek K Owonikoko

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Funding

Boehringer Ingelheim

History

Usage metrics

    Future Oncology

    Categories

    Keywords

    BI 764532DLL3neuroendocrine carcinomasmall-cell lung cancerT-cell engager

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC